S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
Log in

Geovax Labs Stock Price, Forecast & Analysis (OTCMKTS:GOVX)

$0.0007
0.00 (-12.50 %)
(As of 11/15/2019 04:00 PM ET)
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$16.00
Volume58.25 million shs
Average Volume6.39 million shs
Market Capitalization$298,414.20
P/E RatioN/A
Dividend YieldN/A
Beta0.29
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GOVX
Previous SymbolNASDAQ:GOVX
CUSIPN/A
Phone678-384-7220

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$960,000.00
Book Value($0.01) per share

Profitability

Net Income$-2,560,000.00
Net Margins-200.17%

Miscellaneous

Employees8
Market Cap$298,414.20
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive GOVX News and Ratings via Email

Sign-up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.


Geovax Labs (OTCMKTS:GOVX) Frequently Asked Questions

What is Geovax Labs' stock symbol?

Geovax Labs trades on the OTCMKTS under the ticker symbol "GOVX."

How were Geovax Labs' earnings last quarter?

Geovax Labs Inc (OTCMKTS:GOVX) released its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by $0.03. The biotechnology company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.30 million. View Geovax Labs' Earnings History.

When is Geovax Labs' next earnings date?

Geovax Labs is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Geovax Labs.

Has Geovax Labs been receiving favorable news coverage?

News coverage about GOVX stock has been trending neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Geovax Labs earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Geovax Labs.

Who are some of Geovax Labs' key competitors?

What other stocks do shareholders of Geovax Labs own?

Who are Geovax Labs' key executives?

Geovax Labs' management team includes the folowing people:
  • Mr. David Alan Dodd, Chairman, CEO & Pres (Age 69)
  • Dr. Harriet Latham Robinson, Co-Founder, Chief Scientific Officer Emeritus & Director (Age 81)
  • Mr. Mark W. Reynolds CPA, CPA, CFO & Corp. Sec. (Age 57)
  • Dr. Farshad Guirakhoo, Chief Scientific Officer (Age 66)
  • Mr. Donald G. Hildebrand, Founder, Chairman Emeritus & Consultant (Age 78)

How do I buy shares of Geovax Labs?

Shares of GOVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Geovax Labs' stock price today?

One share of GOVX stock can currently be purchased for approximately $0.00.

How big of a company is Geovax Labs?

Geovax Labs has a market capitalization of $298,414.20 and generates $960,000.00 in revenue each year. The biotechnology company earns $-2,560,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis. Geovax Labs employs 8 workers across the globe.View Additional Information About Geovax Labs.

What is Geovax Labs' official website?

The official website for Geovax Labs is http://www.geovax.com/.

How can I contact Geovax Labs?

Geovax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The biotechnology company can be reached via phone at 678-384-7220 or via email at [email protected]


MarketBeat Community Rating for Geovax Labs (OTCMKTS GOVX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about Geovax Labs and other stocks. Vote "Outperform" if you believe GOVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GOVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel